209 related articles for article (PubMed ID: 7884173)
21. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease.
Winterkamp S; Weidenhiller M; Otte P; Stolper J; Schwab D; Hahn EG; Raithel M
Am J Gastroenterol; 2002 Dec; 97(12):3071-7. PubMed ID: 12492192
[TBL] [Abstract][Full Text] [Related]
22. Perianal Crohn's disease.
ten Cate Hoedemaker HO
Neth J Med; 1994 Aug; 45(2):72-5. PubMed ID: 7936009
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the Crohn's Disease Activity Index (CDAI) and the Dutch Index for severity and activity of Crohn's disease. An analysis of the data from the European Cooperative Crohn's Disease Study.
Goebell H; Wienbeck M; Schomerus H; Malchow H
Med Klin (Munich); 1990 Oct; 85(10):573-6. PubMed ID: 2233586
[TBL] [Abstract][Full Text] [Related]
24. Faecal calprotectin in the assessment of Crohn's disease activity.
Gaya DR; Lyon TD; Duncan A; Neilly JB; Han S; Howell J; Liddell C; Stanley AJ; Morris AJ; Mackenzie JF
QJM; 2005 Jun; 98(6):435-41. PubMed ID: 15879440
[TBL] [Abstract][Full Text] [Related]
25. Perianal Crohn's disease: classification and clinical evaluation.
Vermeire S; Van Assche G; Rutgeerts P
Dig Liver Dis; 2007 Oct; 39(10):959-62. PubMed ID: 17720634
[TBL] [Abstract][Full Text] [Related]
26. Oral spherical adsorptive carbon for the treatment of intractable anal fistulas in Crohn's disease: a multicenter, randomized, double-blind, placebo-controlled trial.
Fukuda Y; Takazoe M; Sugita A; Kosaka T; Kinjo F; Otani Y; Fujii H; Koganei K; Makiyama K; Nakamura T; Suda T; Yamamoto S; Ashida T; Majima A; Morita N; Murakami K; Oshitani N; Takahama K; Tochihara M; Tsujikawa T; Watanabe M
Am J Gastroenterol; 2008 Jul; 103(7):1721-9. PubMed ID: 18616656
[TBL] [Abstract][Full Text] [Related]
27. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease.
Summers RW; Elliott DE; Qadir K; Urban JF; Thompson R; Weinstock JV
Am J Gastroenterol; 2003 Sep; 98(9):2034-41. PubMed ID: 14499784
[TBL] [Abstract][Full Text] [Related]
28. Assessing the activity of perianal Crohn's disease: comparison of clinical indices and computer-assisted anal ultrasound.
Losco A; Viganò C; Conte D; Cesana BM; Basilisco G
Inflamm Bowel Dis; 2009 May; 15(5):742-9. PubMed ID: 19023861
[TBL] [Abstract][Full Text] [Related]
29. A survey-based index was validated for measuring disease activity in inflammatory bowel disease. An evaluation study.
Timmer A; Kemptner D; Takses A; Klebl F; Jöckel KH
J Clin Epidemiol; 2009 Jul; 62(7):771-8. PubMed ID: 19110402
[TBL] [Abstract][Full Text] [Related]
30. Cancer of the anus complicating perianal Crohn's disease.
Devon KM; Brown CJ; Burnstein M; McLeod RS
Dis Colon Rectum; 2009 Feb; 52(2):211-6. PubMed ID: 19279414
[TBL] [Abstract][Full Text] [Related]
31. [Anal and perianal lesions in Crohn's disease].
Giordano M; Rebesco B; Blanco G; Torelli I
Minerva Chir; 2001 Dec; 56(6):599-610. PubMed ID: 11721204
[TBL] [Abstract][Full Text] [Related]
32. Perianal Crohn's disease in children and adolescents.
Tolia V
Am J Gastroenterol; 1996 May; 91(5):922-6. PubMed ID: 8633582
[TBL] [Abstract][Full Text] [Related]
33. Extracorporeal photochemotherapy for the treatment of refractory Crohn's disease.
Bisaccia E; Palangio M; Gonzalez J
Transfus Apher Sci; 2007 Oct; 37(2):171-4. PubMed ID: 17993292
[TBL] [Abstract][Full Text] [Related]
34. [Perianal manifestations of Crohn's disease].
Bervar M; Atanasijević T; Sćekić M; Bervar M
Srp Arh Celok Lek; 1981 Feb; 109(2):217-22. PubMed ID: 7313846
[No Abstract] [Full Text] [Related]
35. Perianal Crohn's disease.
Singh B; McC Mortensen NJ; Jewell DP; George B
Br J Surg; 2004 Jul; 91(7):801-14. PubMed ID: 15227686
[TBL] [Abstract][Full Text] [Related]
36. Prospective assessment of Cleveland Global Quality of Life (CGQL) as a novel marker of quality of life and disease activity in Crohn's disease.
Kiran RP; Delaney CP; Senagore AJ; O'Brien-Ermlich B; Mascha E; Thornton J; Fazio VW
Am J Gastroenterol; 2003 Aug; 98(8):1783-9. PubMed ID: 12907333
[TBL] [Abstract][Full Text] [Related]
37. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
38. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?
Gaertner WB; Decanini A; Mellgren A; Lowry AC; Goldberg SM; Madoff RD; Spencer MP
Dis Colon Rectum; 2007 Nov; 50(11):1754-60. PubMed ID: 17899271
[TBL] [Abstract][Full Text] [Related]
39. The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitis.
Shen B; Pardi DS; Bennett AE; Queener E; Kammer P; Hammel JP; LaPlaca C; Harris MS
Am J Gastroenterol; 2009 Jun; 104(6):1468-74. PubMed ID: 19436282
[TBL] [Abstract][Full Text] [Related]
40. The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity.
Clara I; Lix LM; Walker JR; Graff LA; Miller N; Rogala L; Rawsthorne P; Bernstein CN
Am J Gastroenterol; 2009 Jul; 104(7):1754-63. PubMed ID: 19455122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
